comparemela.com

Latest Breaking News On - Amelia marosek - Page 1 : comparemela.com

Boston Pharmaceuticals Announces Positive Phase 2a Results from Monthly and Bi-weekly Dosing with Investigational BOS-580 NASH Program at EASL 2023

CAMBRIDGE, Mass. (BUSINESS WIRE) Jun 21, 2023

United statesUnited kingdomAmelia marosekSophie kornowskiRohit loombaErnesto bertarelliDivision of gastroenterologyInternational liver congressBoston pharmaceuticalsEuropean associationCalifornia san diego schoolPrivate equityGrowth capitalReal assetsHedge fundsBusiness wire

Boston Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting New Phase 2 Clinical Data from BOS-580 NASH Program at EASL 2023

Boston Pharmaceuticals today announced that new results from its ongoing Phase 2a study evaluating BOS-580 for the treatment of non-alcoholic steatohepatitis (NASH) were accepted as a late-breaking poster

United statesRohit loombaErnesto bertarelliGewinn nurAmelia marosekResearch centerBoston pharmaceuticalsEuropean associationLiver international congressVice chiefSan diegoPrivate equityVenture growth capitalReal assetsHedge funds

BeyoND Phase 2b Data Indicates ND0612 Has a Positive Long-Term Safety Profile for People with Parkinson s Disease

/PRNewswire/ NeuroDerm Ltd., a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation, announced positive, long-term safety and tolerability data.

United statesAmelia marosekClin neuropharmacolC warren olanowBoca ratonLaurence salinStuart isaacsonNeuroderm ltdMitsubishi chemical holdings groupMovement disorders centerAmerican academy of neurology annual meetingMitsubishi tanabe pharma corporationRed havas healthPrnewswire neuroderm ltdMichaelj fox foundationMitsubishi tanabe pharma group

vimarsana © 2020. All Rights Reserved.